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Introduction
Progress in diagnostics and immunotherapy for autoim-
mune encephalitis has significantly improved survival rates. 
However, autoimmune encephalitis remains a challenging 
condition, associated with a protracted recovery course and 
uncertain long-term outcome. Clarification of the risk fac-
tors for autoimmune encephalitis, and the development of 
scales to aid with prognostication, may help improve clinical 
management.
This month’s journal club explores three papers relating 
to autoimmune encephalitis. The first paper examines the 
frequency of and risk factors for autoimmune encephalitis 
following herpes simplex encephalitis. The second paper 
describes the development of a score that predicts 1-year 
functional status in patients with anti-NMDA receptor 
encephalitis. The third paper discusses the development of 
a general scale for assessing severity in diverse autoimmune 
encephalitis syndromes.
Frequency, symptoms, risk factors 
and outcomes of autoimmune encephalitis 
after herpes simplex encephalitis: 
a prospective observational study 
and retrospective analysis
It is well established that herpes simplex encephalitis can 
trigger autoimmune encephalitis. This paper explores the 
association between herpes simplex encephalitis and conse-
quent autoimmune encephalitis using prospective (cohort A) 
and retrospective (cohort B) analyses. Cohort A comprised 
51 patients with newly diagnosed herpes simplex encepha-
litis. These patients were followed up at several stages over 
a 12-month period with a neurological assessment and 
evaluation of serum and CSF autoantibody levels. Cohort B 
comprised 48 patients with a clinical diagnosis of autoim-
mune encephalitis following successful treatment of herpes 
simplex encephalitis.
In the prospective analysis, 14 patients (27%) developed 
neurological worsening consistent with probable autoim-
mune encephalitis. All 14 patients (100%) tested positive 
for IgG antibodies; 9 patients tested positive for anti-NMDA 
receptor antibodies, and 5 for other antigens. All patients 
had been negative for neuronal antibodies at onset of her-
pes simplex encephalitis. In contrast, of the 37 patients who 
did not develop clinical autoimmune encephalitis, 11 (30%) 
tested positive for IgG antibodies during follow up. The time 
period between herpes simplex encephalitis and the devel-
opment of autoimmune encephalitis for cohort A patients 
ranged between 7 and 61 days. There were no statistically 
significant differences between clinical symptoms of herpes 
simplex encephalitis, cerebrospinal fluid parameters, radio-
logical findings or treatment duration between patients who 
developed autoimmune encephalitis to those who did not.
In cohort B, 44/48 (92%) had neuronal antibodies either 
against NMDA (34/44) (77%) or against unknown antigens. 
Of all 58 patients who developed autoimmune encephalitis 
across both cohorts, patients younger than 4 years were more 
likely to present with choreoathetosis, whereas patients over 
age 4 years more frequently demonstrated behavioural prob-
lems and psychosis.
Comment: This is a robust study demonstrating a 27% 
probability of developing autoimmune encephalitis fol-
lowing herpes simplex encephalitis. Positive antibodies 
3-week post-diagnosis of herpes simplex encephalitis 
may predict autoimmune encephalitis. Strengths include 
the objectivity of serum and CSF antibody testing and the 
follow-up of patients in the prospective analysis at a num-
ber of different time-points. However, it is unclear which 
autoantibodies, other than anti-NMDA, were tested for, 
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and whether antibodies against unknown antigens found 
in the sera and CSF are genuinely pathogenic.
Armangue et al. (2018) Lancet Neurol 17:760–72.
A score that predicts 1‑year functional 
status in patients with anti‑NMDA receptor 
encephalitis
The objective of this retrospective observational study 
was to construct a grading score that predicts neuro-
logical function 1 year after the diagnosis of NMDAR 
encephalitis.
This study examined a cohort of 382 patients identified 
as having anti-NMDA receptor encephalitis defined by the 
clinical picture as well as positive serum or CSF findings. 
All patient CSF and serum samples were sent either to the 
University of Pennsylvania or the University of Barcelona 
from 200 centres in 35 countries. All patients within the 
cohort had been part of a prior observational study, with 
previously collected data regarding demographics, symp-
tom onset, clinical, laboratory and radiological features, 
time to treatment initiation, time from treatment initiation 
to improvement, and functional status using the modified 
Rankin scale (mRS). Good functional status at 1 year was 
defined as a mRS ≤ 2.
The group analysed a range of clinical factors to deter-
mine predictors of functional status at 1 year using a multi-
variate regression model. Five independent variables were 
identified including: need for ICU admission, delay of treat-
ment initiation beyond 4 weeks of symptom onset, lack of 
clinical improvement 4 weeks after initiating treatment, pres-
ence of an abnormal MRI scan and CSF WBC count > 20 
cells/uL. Points were assigned to each of these variables to 
construct the NEOS score (anti-NMDAr encephalitis 1 year 
functional status score), with a maximum possible score of 
5. A strong association was found between the NEOS score 
and functional status at 1 year, with a NEOS score of 0 relat-
ing to good functional status and higher NEOS scores relat-
ing to greater disability (p < 0.001).
Comment: The use of the NEOS score may aid with 
prognostication and identify a subset of patients who could 
benefit from treatment escalation. However, as the authors 
point out, 1 year functional status provides a snapshot in 
time, and ongoing recovery could be expected beyond this 
time-period. With regards to methodology, the pooling of 
patients from 35 different countries raises questions as to 
variations in treatment and the potential impact of this on 
clinical outcome.
Balu et al. (2019) Neurology Jan 15;92(3):e244–e252.
Development of the clinical assessment 
scale in autoimmune encephalitis (CASE)
This study describes the development of a novel scale for 
assessing severity of disease and evaluating response to 
treatment in patients with diverse autoimmune encephalitis 
syndromes. Currently the modified Rankin Scale is used to 
assess neurological outcome in autoimmune encephalitis, 
however, as the mRS is designed to evaluate disability 
post stroke, a rating scale for autoimmune encephalitis is 
desirable.
Two expert panels developed the scale. Initially, 4 
experts in autoimmune encephalitis generated the key 
clinical determinants of severity of autoimmune encepha-
litis. Thirteen neurologists then reviewed the key items put 
forward by the expert panel and answered whether the item 
was or was not essential for reviewing severity of autoim-
mune encephalitis. The final scale comprised nine items: 
seizure, memory dysfunction, psychiatric symptoms, con-
sciousness, language problem, dyskinesia/dystonia, gait 
instability and ataxia, brainstem dysfunction and weak-
ness, with sub-criteria for each key item giving a possi-
ble score of 0–3, and a maximum score of 27 for all nine 
key items. The scale was tested by three neurologists on a 
development cohort of 50 patients with confirmed autoim-
mune encephalitis, and by two neurologists on a validation 
cohort of 38 patients to evaluate its reliability. The scale 
showed excellent inter-observer and intra-observer reli-
ability and good correlation with the modified Ranking 
Scale (p < 0.001).
Comment: CASE may help to overcome some of the cur-
rent limitations in the assessment of autoimmune enceph-
alitis. However, there are also a number of limitations to 
this study, in particular the key items within the scale were 
drawn up by small panel of neurologists via unclear means. 
Also the small number of assessors applying the scale to 
the development and validation cohorts makes it difficult 
to draw reliable inferences about inter-observer reliability, 
and the length of the scale with multiple subsections may 
also make its use cumbersome in clinical practice. Finally, 
the authors do not provide information as to how the scale 
ratings relate to overall outcome in autoimmune encephalitis 
patients.
Lim et al. (Jan 2019) Ann Neurol 85 (3):352–358.
Conclusion
The first paper discussed raises awareness of the likelihood 
of autoimmune encephalitis following herpes simplex 
encephalitis. Clinicians should have a low threshold to test 
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for autoimmune encephalitis in patients who deteriorate 
following viral encephalitis. The second and third papers 
demonstrate encouraging work in the development of 
assessment scales for autoimmune encephalitis. Although 
treatment and recovery remains an individualised process, 
these scales may help to identify patient subgroups who 
could benefit from novel therapies.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
